Read the highlights:Distinguishing statutory requirements, processing steps and information management recommendations in the context of business roles, actual records and specific business changes.
First distinguishing between existing legal competence and draft guidelines
The document on access to the cosmetics records, published by FDA in January 2026, is still marked as a draft guide for comments and not for implementation. The article discussed the additional statutory competence of MoCRA and the draft description of those competence, and the draft recommendation could not be considered a new rule in force. Enterprises can check their follow-up status through official document pages.
Under what conditions does the FDA have access to the records?
Different powers have their own conditions and scope. Records relating to serious adverse events cannot be confused with records of products that may involve serious adverse health consequences or risk of death. The new section 610 of MoCRA allows FDA to access and copy the records required to judge the associated shaming and serious risks when the statutory conditions are met.
Under article 610 conditions include FDA having reasonable grounds to believe that the cosmetics in question may be inflated and that the use or exposure would result in serious adverse health consequences or death threats; It also provides for requirements such as identification documents for law enforcement officials, written notification and reasonable time, scope and modalities. It cannot be understood on this basis that FDA has unrestricted access to all commercial information under any circumstances.
Which enterprises should be concerned and how should records relate?
Responsible persons, manufacturing or processing facilities and parties collaborating with their information should recognize record-keeping responsibilities in accordance with their legal roles and the actual division of labour. The outsourcing of production by brand parties does not mean that products, labels, complaints or security information can be unmanaged; Manufacturers also need to be able to match actual products to production and quality records.
It is proposed to establish correspondence between product names, formulation versions, batches, responsible persons and physical facilities, and to identify which information is kept in their own custody and which needs to be obtained from partners. This is an enterprise records management proposal that does not imply that all actors have exactly the same obligations under each legal provision.
How can information be organized to avoid ad hoc consolidation?
- Product and version catalogues: names, formulations, labels, production sites and change records can correspond to each other.
- Security support information: identification of sources, applicable products, versions and responsible persons.
- Production and distribution information: Retrieval by product and batch, maintenance of records of the transfer of information between cooperating parties.
- Complaints and information on adverse incidents: distinguishing between original records, follow-up communication and completed assessments.
- Document management arrangements: confirmation of permissions, backups, location of storage and statement of needs support in English.
The addition of a blank template should not be seen as having established a compliance record. Where information is missing, the gaps and sources should be identified and the original information verified and refined so that it cannot be counterfilled or the results of tests, assessments and processing that do not exist should be manufactured.
What are the arrangements for retention periods and information responses?
The presentation of the draft by FDA indicated that poor incident records were usually kept for six years, with qualified small businesses for three years. The note should not be disseminated to all cosmetics documents without distinction in relation to the records of related adverse events; The qualifications of small businesses and the specific applicable rules will also need to be checked separately.
Upon receipt of the FDA actual request, the letter, legal basis, product and range of information shall be checked, focal points shall be designated, the original record maintained and the necessary information aggregated and reviewed. Do not assume a single response period on its own, nor do database listings, platform clearances or holding registered information as a basis for exemption from recording obligations.
Distinction between common error areas and other MoCRA events
- Records access does not mean that every enterprise has to upload all technical information to the FDA on its own initiative.
- Facilities registration and implementation cannot be a substitute for security support and related records management.
- The draft guide was not a final guide, and the recommendations in the note should be identified separately from existing law articles.
- General complaints, adverse incident reports, access to information and product recall are subject to different judgement requirements and should be dealt with on a factual basis.
Official sources are checked with recent information.
- FDA | Records Access Authority for Cosmetic Products Draft Page
- Publication note to the draft FDA: Legal competence and duration of retention
- U.S. Code | 21 U.S.C. 364f: Statutory conditions for access to records
Data check: 2026-11-18. This paper provides general compliance information, and actual correspondence and product-specific requirements are checked against the applicable laws and FDA documents.
Next step: starting with a record gap
An enterprise may first list the product, the subject of responsibility and the inventory of available information, identifying records that are not available, have unclear versions or have no assigned responsibilities. Extended reading:MoCRA Facilities Registration and product listing Guide; ViewableMoCRA Information Maintenance Supportor throughContact PageDescribe the information available and the scope of collaboration required.
Author: Mr. Otsun; Audit: Mr. Toto. Content update and data check: 2026-11-18.